MCID: INT079
MIFTS: 48

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 11 19 5 14 16 71 33
Cholangiocarcinoma 43 71
Peripheral Intrahepatic Cholangiocarcinoma 71
Adenocarcinoma of Intra-Hepatic Bile Ducts 33
Cholangiocarcinoma, Unspecified Site 33
Intrahepatic Bile Duct Carcinoma 11
Peripheral Cholangiocarcinoma 11
Cholangiocarcinoma of Liver 33

Classifications:



External Ids:

Disease Ontology 11 DOID:4928
MeSH 43 D018281
NCIt 49 C35417
SNOMED-CT 68 109842005
ICD10 31 C22.1
ICD11 33 1253728223
UMLS 71 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

GARD: 19 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. Signs and symptoms of Intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching.

MalaCards based summary: Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to sarcomatous intrahepatic cholangiocarcinoma and mucinous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CPS1-IT1 (CPS1 Intronic Transcript 1). The drugs Celecoxib and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and t cells, and related phenotype is neoplasm.

Disease Ontology: 11 A cholangiocarcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree.

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1015)
# Related Disease Score Top Affiliating Genes
1 sarcomatous intrahepatic cholangiocarcinoma 32.9 KRT19 AFP
2 mucinous intrahepatic cholangiocarcinoma 32.8 KRT7 IDH1 CEACAM5
3 cholangiocarcinoma 32.8 TUG1 RASGEF1A MUC4 KRT7 KRT19 IDH2
4 klatskin's tumor 32.2 KRT7 KRT19 IDH1 FGFR2 CPS1-IT1 CEACAM5
5 cholangitis, primary sclerosing 31.3 KRT7 KRT19 CEACAM5 AFP
6 biliary tract cancer 31.3 MUC4 MIR424 MIR214 KDM4C AFP
7 obstructive jaundice 31.3 KRT7 CEACAM5 AFP
8 bile duct adenoma 31.2 KRT7 KRT19 AFP
9 tubular adenocarcinoma 31.2 KRT7 CEACAM5 AFP
10 hepatocellular carcinoma 31.0 TUG1 MUC4 MIR424 MIR22 MIR214 MIR212
11 bile duct cysts 31.0 KRT7 KRT19 CEACAM5 AFP
12 bile duct cancer 30.9 MUC4 MIR424 MIR214 KRT7 KRT19 IDH1
13 cholangiolocellular carcinoma 30.9 KRT7 KRT19 IDH1 CEACAM5 AFP
14 adenosquamous carcinoma 30.8 MUC4 KRT7 KRT19 CEACAM5
15 intrahepatic gall duct cancer 30.8 KRT7 KRT19
16 appendix adenocarcinoma 30.8 KRT7 CEACAM5
17 lymphoepithelioma-like carcinoma 30.8 KRT7 KRT19
18 cholecystolithiasis 30.8 CEACAM5 AFP
19 hepatic tuberculosis 30.7 CEACAM5 AFP
20 biliary papillomatosis 30.7 KRT7 KRT19 CEACAM5
21 gallbladder cancer 30.7 TUG1 MIR214 KRT7 KRT19 IDH1 FGFR2
22 fibrolamellar carcinoma 30.5 KRT7 KRT19 AFP
23 neuroendocrine carcinoma 30.5 KRT7 KRT19 AFP
24 bile duct cystadenocarcinoma 30.5 KRT7 CEACAM5 AFP
25 ascending colon cancer 30.5 KRT7 CEACAM5
26 multiple enchondromatosis, maffucci type 30.5 KDM4C IDH2 IDH1
27 mucinous cystadenocarcinoma 30.5 KRT7 CEACAM5 AFP
28 benign mesothelioma 30.4 KRT7 KRT19 CEACAM5
29 retinitis pigmentosa 11 30.4 TUG1 KDM4C CCAT2 CCAT1
30 abdominal tuberculosis 30.4 CEACAM5 AFP
31 gastric adenocarcinoma 30.4 MUC4 FGFR2 CEACAM5 AFP
32 cystadenoma 30.4 MUC4 KRT7 CEACAM5 AFP
33 gastric cancer 30.4 TUG1 MUC4 MIR214 KRT19 FGFR2 CEACAM5
34 hepatoblastoma 30.4 TUG1 KRT7 KRT19 AFP
35 bile duct disease 30.4 MIR424 MIR214 KRT7 KRT19 KDM4C IDH1
36 intrahepatic bile duct adenoma 30.4 KRT7 KRT19 CEACAM5 AFP
37 pancreatic cancer 30.4 TUG1 MUC4 MIR424 MIR376A1 MIR214 MIR212
38 squamous cell carcinoma 30.3 TUG1 KRT7 KRT19 KDM4C FGFR2 CEACAM5
39 hematologic cancer 30.3 MIR424 MIR22 MIR214 MIR127 KDM4C
40 stomach disease 30.3 MIR424 MIR22 MIR214 MIR212 MIR127
41 wilms tumor 1 30.3 KRT7 KDM4C CEACAM5 AFP
42 biliary tract benign neoplasm 30.3 KRT7 KRT19 CEACAM5 AFP
43 lymphoma, non-hodgkin, familial 30.3 MIR424 MIR22 MIR214 MIR127 KDM4C
44 primary biliary cholangitis 30.3 MIR212 KRT7 KRT19 AFP
45 teratoma 30.3 KRT7 CEACAM5 AFP
46 krukenberg carcinoma 30.3 KRT7 CEACAM5 AFP
47 lung squamous cell carcinoma 30.3 TUG1 KRT19 FGFR2 CEACAM5 CCAT2 CCAT1
48 endodermal sinus tumor 30.2 KRT7 CEACAM5 AFP
49 gastrointestinal system cancer 30.2 MIR424 MIR22 MIR214 MIR212 MIR127 KDM4C
50 ovarian cancer 30.2 TUG1 MUC4 MIR424 MIR214 KRT7 FGFR2

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain; malaise

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP CEACAM5 FGFR2 IDH2 KDM4C KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Desflurane Approved Phase 4 57041-67-5 42113
4
Etomidate Approved Phase 4 33125-97-2 667484
5
Meperidine Approved Phase 4 57-42-1 4058
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
8
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
9 Anti-Inflammatory Agents Phase 4
10 Antirheumatic Agents Phase 4
11 Analgesics, Non-Narcotic Phase 4
12 Platelet Aggregation Inhibitors Phase 4
13 Anesthetics, Inhalation Phase 4
14 Cyclooxygenase Inhibitors Phase 4
15 Cyclooxygenase 2 Inhibitors Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Anesthetics Phase 4
18
Bismuth Phase 4 7440-69-9 105143
19 Analgesics Phase 4
20 Anti-Anxiety Agents Phase 4
21 Anesthetics, Intravenous Phase 4
22 Anesthetics, General Phase 4
23 Hypnotics and Sedatives Phase 4
24 Analgesics, Opioid Phase 4
25 GABA Modulators Phase 4
26 Narcotics Phase 4
27 Omega 3 Fatty Acid Phase 4
28
Ulipristal acetate Phase 4 126784-99-4 13559282 130904
29 Calcium, Dietary Phase 4
30
Calcium Nutraceutical Phase 4 7440-70-2 271
31
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
32
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 3 14769-73-4 26879
33
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
34
Infigratinib Approved, Investigational Phase 3 872511-34-7 53235510
35
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
36
Lenvatinib Approved, Investigational Phase 3 417716-92-8 9823820
37
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
38
Citalopram Approved Phase 3 59729-32-7, 59729-33-8 2771
39
Dexetimide Withdrawn Phase 3 21888-98-2 30843
40 Anti-Bacterial Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42 FOLFIRINOX Phase 2, Phase 3
43 Emetics Phase 3
44 Tin Fluorides Phase 2, Phase 3
45 Antiparasitic Agents Phase 3
46 Anthelmintics Phase 3
47 Albumin-Bound Paclitaxel Phase 2, Phase 3
48 Antimitotic Agents Phase 2, Phase 3
49 Tubulin Modulators Phase 2, Phase 3
50 Photosensitizing Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 643)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
2 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
3 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
4 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
5 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
6 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
7 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
8 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
9 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
10 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
11 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
12 Cholangiocarcinoma Treatment With Radiofrequency Ablation or Photodynamic Therapy: a Randomized Controlled Trial Recruiting NCT05551299 Phase 4 Photosensitizer
13 Recombinant Human Adenovirus Type 5 Combined With Hepatic Artery Infusion Chemotherapy of FOLFOX in Patients With Intrahepatic Mass-forming Cholangiocarcinoma: a Single-site, Single-arm, Prospective Study Not yet recruiting NCT05124002 Phase 4 Recombinant Human Adenovirus Type 5;HAIC of FOLFOX
14 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Unknown status NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
15 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
16 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Unknown status NCT03345303 Phase 3 Bortezomib
17 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
18 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Unknown status NCT02108145 Phase 2, Phase 3
19 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
20 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
21 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
22 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Unknown status NCT01470443 Phase 3 Oxaliplatin
23 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
24 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Completed NCT02989857 Phase 3 AG-120;Placebo
25 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
26 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
27 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
28 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
29 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
30 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
31 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
32 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
33 A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors Recruiting NCT04669496 Phase 2, Phase 3 Neoadjuvant treatment
34 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
35 Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT04961970 Phase 3 oxaliplatin , fluorouracil, and leucovorin;gemcitabine and cisplatin
36 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
37 A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 Recruiting NCT04093362 Phase 3 TAS-120;Cisplatin/Gemcitabine
38 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
39 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
40 Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
41 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
42 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Active, not recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
43 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Active, not recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
44 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
45 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Active, not recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
46 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
47 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Active, not recruiting NCT04066491 Phase 2, Phase 3 M7824;Placebo;Gemcitabine;Cisplatin
48 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Active, not recruiting NCT02853474 Phase 3
49 A Phase III, Randomized, Three-arm, Double-blind, Placebo-controlled, International Multi-center Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Lenvatinib and Gemcitabine-based Chemotherapy Compared With Gemcitabine-based Chemotherapy as First-line Treatment in Patients With Unresectable Advanced Intrahepatic Cholangiocarcinoma (ICC) Not yet recruiting NCT05342194 Phase 3 Toripalimab;Lenvatinib mesylate capsules;Placebo IV;Oral placebo;Oxaliplatin for injection;Gemcitabine hydrochloride;Cisplatin
50 A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen Not yet recruiting NCT05506943 Phase 2, Phase 3 CTX-009;Paclitaxel

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

Organs/tissues related to Intrahepatic Cholangiocarcinoma:

MalaCards : Liver, Lymph Node, T Cells, Breast, Colon, Pancreas, Kidney

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 4228)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 62 46
19755794 2009
2
Past, Present, and Future Management of Localized Biliary Tract Malignancies. 62
36410923 2023
3
Predicting overall and recurrence-free survival in patients with intrahepatic cholangiocarcinoma using the MEGNA score: A multi-institutional analysis. 62
36106350 2023
4
Textbook oncologic outcomes and regionalization among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. 62
36136327 2023
5
A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. 62
36181621 2022
6
Extreme In Situ Liver Surgery Under Total Vascular Exclusion with Right Hepatic Vein and Inferior Vena Cava Grafts for an Intrahepatic Cholangiocarcinoma. 62
36463359 2022
7
Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing. 62
36469154 2022
8
We Asked the Experts: Role of Lymphadenectomy in Surgical Management of Intrahepatic Cholangiocarcinoma. 62
36469094 2022
9
Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. 62
35129063 2022
10
Liver transplantation for patients with intrahepatic cholangiocarcinoma. 62
35613995 2022
11
Laparoscopic left hepatectomy and combined resection and reconstruction of right hepatic artery for intrahepatic cholangiocarcinoma. 62
35753576 2022
12
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. 62
35272564 2022
13
Hepatic Artery Infusion Pumps: A Surgical Toolkit for Intraoperative Decision-Making and Management of Hepatic Artery Infusion-Specific Complications. 62
36346892 2022
14
Bleeding after percutaneous transhepatic biliary drainage due to arterial injury: A case study in patient with stable hemodynamic. 62
36263331 2022
15
Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100. 62
36272467 2022
16
Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway. 62
36410274 2022
17
Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy: A Case Report and Review of the Literature. 62
36381099 2022
18
EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling. 62
36350008 2022
19
Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? 62
36255606 2022
20
Survival and Causes of Death among Patients with Intrahepatic Cholangiocarcinoma in the United States from 2000 to 2018. 62
36099432 2022
21
Development and validation of an LC-MS/MS method for D- and L-2-hydroxyglutaric acid measurement in cerebrospinal fluid, urine and plasma: application to glioma. 62
36453751 2022
22
Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21. 62
36114826 2022
23
Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. 62
35988690 2022
24
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma. 62
36123506 2022
25
Results of Intrahepatic Cholangiocarcinoma Resections: a Single-Center Analysis. 62
34989985 2022
26
The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia. 62
36404533 2022
27
Glycoproteomic analysis reveals the effects of bisecting GlcNAc in intrahepatic cholangiocarcinoma. 62
36322335 2022
28
FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling. 62
36348252 2022
29
Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study. 62
36405111 2022
30
Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015. 62
36384474 2022
31
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. 62
36462464 2022
32
Tumor-associated macrophages in liver cancer: From mechanisms to therapy. 62
36069342 2022
33
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. 62
36335135 2022
34
Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2. 62
36335201 2022
35
Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition. 62
36443822 2022
36
Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma. 62
36369960 2022
37
Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90Y radioembolization: A multicenter retrospective study. 62
36328487 2022
38
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma. 62
36334155 2022
39
Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature. 62
36405269 2022
40
Modification of the AJCC/UICC 8th edition staging system for intrahepatic cholangiocarcinoma: proposal for an alternative staging system from cholangiocarcinoma-prevalent Northeast Thailand. 62
35810105 2022
41
Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. 62
35738508 2022
42
Facility Volume Thresholds for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Hepatectomy for Primary Liver Tumors. 62
36443556 2022
43
A Case of Multicystic Biliary Hamartoma with a Marked Peribiliary Gland Component Successfully Treated by Purely Laparoscopic Anatomical Liver Resection. 62
36449146 2022
44
Is left lateral sectionectomy of the liver without operative site drainage safe and effective? 62
35995584 2022
45
Laparoscopic isolated liver segmentectomy 8 for malignant tumors: techniques and comparison of surgical results with the open approach using a propensity score-matched study. 62
36102966 2022
46
ASO Visual Abstract: Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis. 62
35904657 2022
47
Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. 62
36174301 2022
48
Futibatinib: First Approval. 62
36441501 2022
49
Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression. 62
35340039 2022
50
Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. 62
35506195 2022

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APC NM_000038.6(APC):c.4440G>C (p.Gln1480His) SNV Uncertain Significance
482375 rs876659881 GRCh37: 5:112175731-112175731
GRCh38: 5:112840034-112840034
2 APC NM_000038.6(APC):c.8461G>A (p.Asp2821Asn) SNV Uncertain Significance
559959 rs1554089164 GRCh37: 5:112179752-112179752
GRCh38: 5:112844055-112844055
3 APC NM_000038.6(APC):c.8332G>T (p.Ala2778Ser) SNV Uncertain Significance
133537 rs587778046 GRCh37: 5:112179623-112179623
GRCh38: 5:112843926-112843926

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate metabolic process GO:0006102 9.26 IDH2 IDH1
2 glyoxylate cycle GO:0006097 8.92 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.46 MIR424 MIR214 MIR212 MIR127
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
3 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR424 MIR22 MIR214 MIR212 MIR127

Sources for Intrahepatic Cholangiocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....